Zobrazeno 1 - 10
of 478
pro vyhledávání: '"David A. Wolk"'
Autor:
Chengjie Xiong, Jingqin Luo, David A. Wolk, Leslie M. Shaw, Erik D. Roberson, Charles F. Murchison, Rachel L. Henson, Tammie L. S. Benzinger, Quoc Bui, Folasade Agboola, Elizabeth Grant, Emily N. Gremminger, Krista L. Moulder, David S. Geldmacher, Olivio J. Clay, Ganesh Babulal, Carlos Cruchaga, David M. Holtzman, Randall J. Bateman, John C. Morris, Suzanne E. Schindler
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers
Externí odkaz:
https://doaj.org/article/7e17f1f8091f4e35b67e41ede981da17
Autor:
Sadhana Ravikumar, Amanda E. Denning, Sydney Lim, Eunice Chung, Niyousha Sadeghpour, Ranjit Ittyerah, Laura E. M. Wisse, Sandhitsu R. Das, Long Xie, John L. Robinson, Theresa Schuck, Edward B. Lee, John A. Detre, M. Dylan Tisdall, Karthik Prabhakaran, Gabor Mizsei, Maria Mercedes Iñiguez de Onzono Martin, Maria del Mar Arroyo Jiménez, Monica Mũnoz, Maria del Pilar Marcos Rabal, Sandra Cebada Sánchez, José Carlos Delgado González, Carlos de la Rosa Prieto, David J. Irwin, David A. Wolk, Ricardo Insausti, Paul A. Yushkevich
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Our current understanding of the spread and neurodegenerative effects of tau neurofibrillary tangles (NFTs) within the medial temporal lobe (MTL) during the early stages of Alzheimer’s Disease (AD) is limited by the presence of confounding
Externí odkaz:
https://doaj.org/article/056f36ce471b4eba989dc86723aa6f3b
Autor:
Sanaz Arezoumandan, Katheryn A.Q. Cousins, Daniel T. Ohm, MaKayla Lowe, Min Chen, James Gee, Jeffrey S. Phillips, Corey T. McMillan, Kelvin C. Luk, Andres Deik, Meredith A. Spindler, Thomas F. Tropea, Daniel Weintraub, David A. Wolk, Murray Grossman, Virginia Lee, Alice S. Chen‐Plotkin, Edward B. Lee, David J. Irwin
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 3, Pp 673-685 (2024)
Abstract Objective Alzheimer's disease neuropathologic change and alpha‐synucleinopathy commonly co‐exist and contribute to the clinical heterogeneity of dementia. Here, we examined tau epitopes marking various stages of tangle maturation to test
Externí odkaz:
https://doaj.org/article/cdc2ad75ef8743d99fac2e3feb9bcc6b
Autor:
Zhijian Yang, Junhao Wen, Ahmed Abdulkadir, Yuhan Cui, Guray Erus, Elizabeth Mamourian, Randa Melhem, Dhivya Srinivasan, Sindhuja T. Govindarajan, Jiong Chen, Mohamad Habes, Colin L. Masters, Paul Maruff, Jurgen Fripp, Luigi Ferrucci, Marilyn S. Albert, Sterling C. Johnson, John C. Morris, Pamela LaMontagne, Daniel S. Marcus, Tammie L. S. Benzinger, David A. Wolk, Li Shen, Jingxuan Bao, Susan M. Resnick, Haochang Shou, Ilya M. Nasrallah, Christos Davatzikos
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Disease heterogeneity has been a critical challenge for precision diagnosis and treatment, especially in neurologic and neuropsychiatric diseases. Many diseases can display multiple distinct brain phenotypes across individuals, potentially r
Externí odkaz:
https://doaj.org/article/e4408877453444c49479a4dba3887d8a
Autor:
Jeffrey S. Phillips, Nagesh Adluru, Moo K. Chung, Hamsanandini Radhakrishnan, Christopher A. Olm, Philip A. Cook, James C. Gee, Katheryn A. Q. Cousins, Sanaz Arezoumandan, David A. Wolk, Corey T. McMillan, Murray Grossman, David J. Irwin
Publikováno v:
Frontiers in Neuroscience, Vol 18 (2024)
IntroductionMultimodal evidence indicates Alzheimer’s disease (AD) is characterized by early white matter (WM) changes that precede overt cognitive impairment. WM changes have overwhelmingly been investigated in typical, amnestic mild cognitive imp
Externí odkaz:
https://doaj.org/article/982254d1016246fcba223287b0b73d9f
Autor:
Katheryn A. Q. Cousins, David J. Irwin, Alice Chen‐Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 5, Pp 802-813 (2023)
Abstract Objective Within Lewy body spectrum disorders (LBSD) with α‐synuclein pathology (αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of clinical outcomes, including cognitive impairment and decline. Plasma p
Externí odkaz:
https://doaj.org/article/be506e0f18724aafa19268390fc0a285
Autor:
Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich, David A. Wolk, for the Alzheimer’s Disease Neuroimaging Initiative
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-14 (2023)
Abstract Background Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of plasma and structu
Externí odkaz:
https://doaj.org/article/492d55f064a44fedb00d9d01939480f8
Autor:
Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen‐Plotkin, Leslie M. Shaw, the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 1, Pp 18-31 (2023)
Abstract Objective To determine if plasma tau phosphorylated at threonine 181 (p‐tau181) distinguishes pathology‐confirmed Alzheimer's disease (AD) from normal cognition (NC) adults, to test if p‐tau181 predicts cognitive and functional decline
Externí odkaz:
https://doaj.org/article/3b999f9709d54025a05894541cc30c3f
Autor:
Yi-An Ko, Jeffrey T. Billheimer, Nicholas N. Lyssenko, Alexandra Kueider-Paisley, David A. Wolk, Steven E. Arnold, Yuk Yee Leung, Leslie M. Shaw, John Q. Trojanowski, Rima F. Kaddurah-Daouk, Mitchel A. Kling, Daniel J. Rader
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-12 (2022)
Abstract Background Alzheimer’s disease (AD) shares risk factors with cardiovascular disease (CVD) and dysregulated cholesterol metabolism is a mechanism common to both diseases. Cholesterol efflux capacity (CEC) is an ex vivo metric of plasma high
Externí odkaz:
https://doaj.org/article/eeeeb48808c64eb8b61af883746034bd
Autor:
Ana Sofía Ríos, Simón Oxenford, Clemens Neudorfer, Konstantin Butenko, Ningfei Li, Nanditha Rajamani, Alexandre Boutet, Gavin J. B. Elias, Jurgen Germann, Aaron Loh, Wissam Deeb, Fuyixue Wang, Kawin Setsompop, Bryan Salvato, Leonardo Brito de Almeida, Kelly D. Foote, Robert Amaral, Paul B. Rosenberg, David F. Tang-Wai, David A. Wolk, Anna D. Burke, Stephen Salloway, Marwan N. Sabbagh, M. Mallar Chakravarty, Gwenn S. Smith, Constantine G. Lyketsos, Michael S. Okun, William S. Anderson, Zoltan Mari, Francisco A. Ponce, Andres M. Lozano, Andreas Horn
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Deep brain stimulation has been investigated as a potential treatment for cognitive impairments in Alzheimer’s disease. Here the authors carry out post hoc analysis of multi-center cohorts to investigate the anatomical and functional correlates of
Externí odkaz:
https://doaj.org/article/44042e8fc7c347909735b26f535f79b5